. 2019 Jun 20;23:225. doi: 10.1186/s13054-019-2504-8

Table 3.

Consensus statements for potential actions after positive and negative [TIMP-2]•[IGFBP7] testing

Positive test (> 0.3)	Negative test (≤ 0.3)
• Discontinue all nonessential nephrotoxins (e.g., NSAIDs) • Avoid vancomycin or dose adjust • Goal-directed fluid/diuretic management*	• Standard of care or fast-track • Repeat [TIMP-2]•[IGFBP7] test if additional exposures occur • Consider diuretics to maintain fluid balance
• Discontinue all ACE inhibitors and/or ARBs • Maintain close UO monitoring • Review meds with clinical pharmacist • Retain invasive hemodynamic monitoring • Avoid saline
• Consult nephrology • Repeat [TIMP-2]•[IGFBP7] test in 12–24 h • Consult intensive care

Positive test (> 0.3)

Negative test (≤ 0.3)

• Discontinue all nonessential nephrotoxins (e.g., NSAIDs)

• Avoid vancomycin or dose adjust

• Goal-directed fluid/diuretic management*

• Standard of care or fast-track

• Repeat [TIMP-2]•[IGFBP7] test if additional exposures occur

• Consider diuretics to maintain fluid balance

• Discontinue all ACE inhibitors and/or ARBs

• Maintain close UO monitoring

• Review meds with clinical pharmacist

• Retain invasive hemodynamic monitoring

• Avoid saline

• Consult nephrology

• Repeat [TIMP-2]•[IGFBP7] test in 12–24 h

• Consult intensive care

*Includes bedside ultrasound, and functional hemodynamic monitoring

Actions are listed in order of priority. High priority (> 30 out of a possible 48) was assigned to the top 5 actions. Actions that received a score < 12 (equivalent to low priority by all participants and more than 25% of participants not supporting at all) were removed from the list